A body shape index (ABSI) reflects body composition changes in response to testosterone treatment in obese men

R Hoermann; MNT Fui; JC Krakauer; NY Krakauer; M Grossmann

Journal article

A body shape index (ABSI) reflects body composition changes in response to testosterone treatment in obese men

R Hoermann, MNT Fui, JC Krakauer, NY Krakauer, M Grossmann

International Journal of Obesity | NATURE PUBLISHING GROUP | Published : 2019

DOI: 10.1038/s41366-018-0311-y

Abstract

Background: Interventions such as testosterone treatment may change body composition and metabolic outcomes without substantial changes in weight and BMI. Objectives: Using testosterone treatment as a paradigm, we hypothesized that a body shape index (ABSI) reflects body composition changes more accurately than traditional markers, such as weight, BMI and waist circumference. Intervention: Secondary analysis of a 56-week RCT in 100 dieting obese men with low–normal testosterone receiving testosterone treatment or placebo, and subsequent off-treatment follow-up. Results: At the end of the trial period, ABSI—unlike weight, BMI or waist circumference—had significantly decreased in the treatment..

View full abstract

University of Melbourne Researchers

Mathis Grossmann Author

Mark Ng Tang Fui Author

Related Projects (2)

A CLINICAL TRIAL TO ASSESS THE EFFECT OF TESTOSTERONE TREATMENT COMBINED WITH DIETARY RESTRICTION ON BODY FAT MASS AND MUSCLE FUNCTION IN OBESE MEN

Obesity, an increasing health and economic burden, is associated with lowered testosterone levels in men. While both dietary restriction and..

CONTROL OF MUSCULOSKELETAL FUNCTION AND INSULIN RESISTANCE BY ANDROGENS IN MALES

Male sex hormone or androgen deficiency (AD) is a common, but under-diagnosed condition. AD decreases general well being and contributes to ..

Grants

Funding Acknowledgements

MNTF was supported by a postgraduate scholarship (1055305) and MG by a Career Development Fellowship (1024139), both from the National Health and Medical Research Council (Australia). Bayer Pharma AG (Berlin, Germany) provided testosterone, placebo and financial support to conduct investigations during the RCT phase but did not provide funding for the extended follow-up study. Bayer Pharma AG had no role in trial design, data analysis or writing the paper.